Pfizer Inc.

New Capabilities

Co-developer; seeking third-party commercialization partner

For 25 years, drug companies have tried to design medicines that don't just block harmful proteins but destroy them outright. On May 1, the U.S. Food and Drug Administration (FDA) approved the first one. VEPPANU, developed by biotech Arvinas and Pfizer, treats a hard-to-treat form of metastatic breast cancer by hijacking the cell's own garbage-disposal system to shred a mutated estrogen receptor that fuels the tumor.

Updated Yesterday

New Capabilities

Lead commercialization partner for the Lyme disease vaccine; planning 2026 FDA submission

The last Lyme disease vaccine was pulled from the market in 2002 after unfounded safety fears destroyed demand. Twenty-four years later, Pfizer and French biotech Valneva announced that their replacement candidate showed 73% efficacy in a Phase 3 trial of over 9,000 participants, and said they will seek Food and Drug Administration (FDA) approval this year with a possible launch in late 2027.

Updated Mar 23

New Capabilities

Donating antibiotics through 2030

For the first time since records began, fewer than 100 million people need treatment for trachoma—a bacterial eye disease that's been blinding humans since ancient Egyptian times. The number at risk has cratered 94% since 2002, from 1.5 billion to 97 million. Twenty-seven countries have eliminated it entirely, making trachoma one of the success stories celebrated at World NTD Day 2026 on January 30.

Updated Jan 30